Steven Cohen’s Cytek Biosciences CTKB Stock Holding History

Steven Cohen’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.87M	Buy	+422,361	New	+$1.8M	﹤0.01%	2433
2026 Q1	–	Sell	-114,256	Closed	-$577K	–	3896
2025 Q4	$577K	Sell	114,256 -73,362	-39%	-$341K	﹤0.01%	3169
2025 Q3	$651K	Buy	+187,618	New	+$704K	﹤0.01%	1831
2025 Q2	–	Sell	-17,496	Closed	-$70.2K	–	2262
2025 Q1	$70.2K	Sell	17,496 -371,863	-96%	-$1.93M	﹤0.01%	1941
2024 Q4	$2.53M	Buy	+389,359	New	+$2.32M	0.01%	1163
2023 Q1	–	Sell	-812,662	Closed	-$8.3M	–	2289
2022 Q4	$8.3M	Buy	812,662 +139,175	+21%	+$1.87M	0.03%	612
2022 Q3	$9.91M	Sell	673,487 -862,592	-56%	-$11.2M	0.04%	508
2022 Q2	$16.5M	Buy	1,536,079 +905,079	+143%	+$9.01M	0.07%	366
2022 Q1	$6.8M	Buy	+631,000	New	+$8.52M	0.03%	615

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Steven Cohen's CTKB Position: Q2 2026 in Review

Steven Cohen opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 422,361 shares worth $1.87M. The stake represents ﹤0.01% of the portfolio and ranks #2433 among its holdings. This is a return to the name: Steven Cohen previously reported a position in CTKB as recently as Q4 2025.

Steven Cohen first reported a position in CTKB in Q1 2022 and has held it in 9 quarters since. The position peaked at $16.5M in Q2 2022. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Steven Cohen held 422,361 shares of Cytek Biosciences worth $1.87M as of Q2 2026.
Cytek Biosciences was a new Steven Cohen position in Q2 2026.
Cytek Biosciences made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #2433 holding.
Steven Cohen first reported a position in Cytek Biosciences in Q1 2022 and has held it in 9 quarters since.
Steven Cohen's Cytek Biosciences position peaked at $16.5M in Q2 2022.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.